Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Understanding Your LabsUnderstanding Your Labs
          
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Replication Capacity and HIV disease progression
May 21, 2007

I recently seroconverted two months ago. Shortly afterwards, the HIV clinic that I being supervised at did a resistance test. Gladly I was found to have no drug resistances, however my Viral Replication Capacity was found to be above average at 130%. What are the repercussions of such a replication capacity, and is this an indicator that I my HIV disease may progress more rapidly? Is this an indicator that I should perhaps consider starting a medication such as Atripla?

Response from Dr. Holodniy

The replication capacity assay has not been shown to be definitively predictive of disease progression. Your RC is in the normal range, and reflects a wild type virus, that is, one that does not have any resistance mutations. Your don't indicate what your CD4 count or viral load are, so it is difficult to say whether treatment is indicated.



Previous
shingles
Next
bloating

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement